الفهرس 
Hepatitis C Virus (HCV)Only 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
Background: HCV is one of the leading agents that cause liver failure, and hepatocellular carcinoma and is the most relevant reason for liver transplantation. HCV infects about 3% of the world population; 130–200 million people are estimated to be chronically infected globally. Alarming news is that 350,000 people worldwide die from HCV-related disease every year . For more than 20 years, HCV has been taking the attention of the health professionals, and now, well recognized that HCV is actually a major global health problem.
Aim of The Work: The aim of this study is to measure the serum level of interleukin 22 in chronic hepatitis C patients and its relationship with severity of the liver disease.
Patient and Methods: This study will be conducted on 6o patients with chronic hepatitis c virus infection where 30 patients developed complications of chronic hepatitis c infection with meld score >15and 30 patients without evidence of complicated chronic hepatits c infection with meld score <15 and 20 healthy subjects as control group . Patients and controls will be selected from department of Internal Medicine and Gastroenterology in Ain Shams University Hospitals and Hepatology department in National Hepatology and Tropical Medicine Research Institute.
Result: In the current study, the group of chronic hepatitis c patients reported significant decrease in the serum level of interleukin 22 than controls, also interleukin 22 showed no significant discrimination value to detect severity of liver disease between patients with chronic hepatits c infection .
Conclusion: Interleukin 22 is decreased in patients with chronic hepatitis c infection more than healthy individuals.Interleukin22 has poor value for discrimination between patients with chronic HCV infection and a poor marker for detection of severity of liver disease